E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers V > Headlines for ViroPharma Inc. > News item
Published on 10/13/2006 in the Prospect News Biotech Daily.

JMP keeps ViroPharma at market outperform

JMP Securities analyst Adam Cutler reiterated ViroPharma Inc. at market outperform. According to the analyst, the company's phase 3 drug maribavir for cytomegalovirus is an underappreciated asset and could be approved in 2009, with peak sales of more than $400 million. Shares of the Exton, Pa.-based pharmaceutical company were up 22 cents, or 1.81%, at $12.36. (Nasdaq: VPHM)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.